Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Molecular biology underlying the clinical heterogeneity of prostate cancer: an update.

Mackinnon AC, Yan BC, Joseph LJ, Al-Ahmadie HA.

Arch Pathol Lab Med. 2009 Jul;133(7):1033-40. doi: 10.1043/1543-2165-133.7.1033. Review.

PMID:
19642730
2.

Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.

Winnes M, Lissbrant E, Damber JE, Stenman G.

Oncol Rep. 2007 May;17(5):1033-6.

PMID:
17390040
4.

Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.

Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, Montie JE, Rubin MA, Pienta KJ, Roulston D, Shah RB, Varambally S, Mehra R, Chinnaiyan AM.

Nature. 2007 Aug 2;448(7153):595-9.

5.

Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer.

Hofer MD, Kuefer R, Maier C, Herkommer K, Perner S, Demichelis F, Paiss T, Vogel W, Rubin MA, Hoegel J.

Cancer Res. 2009 Jan 15;69(2):640-6. doi: 10.1158/0008-5472.CAN-08-2008.

6.

Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer.

Rubin MA, Chinnaiyan AM.

Lab Invest. 2006 Nov;86(11):1099-102. Epub 2006 Sep 18.

7.

[Frequent gene fusion in prostate cancer: clinical applications in diagnosis, prognosis and therapy].

Schmidt F, Scheble V, Mertz K, Perner S, Rubin MA.

Dtsch Med Wochenschr. 2009 Jul;134(28-29):1483-6. doi: 10.1055/s-0029-1225305. Epub 2009 Jul 1. Review. German.

PMID:
19572250
8.

Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer.

Hermans KG, Boormans JL, Gasi D, van Leenders GJ, Jenster G, Verhagen PC, Trapman J.

Clin Cancer Res. 2009 Oct 15;15(20):6398-403. doi: 10.1158/1078-0432.CCR-09-1176. Epub 2009 Oct 13.

9.

A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis.

Lapointe J, Kim YH, Miller MA, Li C, Kaygusuz G, van de Rijn M, Huntsman DG, Brooks JD, Pollack JR.

Mod Pathol. 2007 Apr;20(4):467-73. Epub 2007 Mar 2.

10.

Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.

Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP, Ludkovski O, Zielenska M, Soares FA, Squire JA.

Mod Pathol. 2008 Dec;21(12):1451-60. doi: 10.1038/modpathol.2008.96. Epub 2008 May 23.

11.

Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.

Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, Prensner JR, Cao X, Singla N, Montie JE, Varambally S, Mehra R, Chinnaiyan AM.

Cancer Res. 2008 Jan 1;68(1):73-80. doi: 10.1158/0008-5472.CAN-07-5352.

12.

Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases.

Mehra R, Han B, Tomlins SA, Wang L, Menon A, Wasco MJ, Shen R, Montie JE, Chinnaiyan AM, Shah RB.

Cancer Res. 2007 Sep 1;67(17):7991-5.

13.

Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy.

Koivisto P, Hyytinen E, Palmberg C, Tammela T, Visakorpi T, Isola J, Kallioniemi OP.

Am J Pathol. 1995 Dec;147(6):1608-14.

14.

TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, Cao X, Wei JT, Rubin MA, Shah RB, Chinnaiyan AM.

Cancer Res. 2006 Apr 1;66(7):3396-400.

15.

Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer.

Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM, Shah RB.

Mod Pathol. 2007 May;20(5):538-44. Epub 2007 Mar 2.

16.

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.

Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP.

N Engl J Med. 1995 May 25;332(21):1393-8.

17.

A sensitive array-based assay for identifying multiple TMPRSS2:ERG fusion gene variants.

Lu Q, Nunez E, Lin C, Christensen K, Downs T, Carson DA, Wang-Rodriguez J, Liu YT.

Nucleic Acids Res. 2008 Nov;36(20):e130. doi: 10.1093/nar/gkn585. Epub 2008 Sep 15.

18.

Detection of TMPRSS2 gene deletions and translocations in carcinoma, intraepithelial neoplasia, and normal epithelium of the prostate by direct fluorescence in situ hybridization.

Zhang S, Pavlovitz B, Tull J, Wang Y, Deng FM, Fuller C.

Diagn Mol Pathol. 2010 Sep;19(3):151-6. doi: 10.1097/PDM.0b013e3181bb216a.

PMID:
20736744
19.

[TMPRSS2-ETS gene fusion in prostate cancer].

Perner S, Schmidt FH, Hofer MD, Kuefer R, Rubin M.

Urologe A. 2007 Jul;46(7):754-60. Review. German.

PMID:
17458530
20.

[Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].

Dai MJ, Chen LL, Zheng YB, Chen W, Tao ZH, Weng ZL, Wu XL, Li CD, Chen ZG, Chen XD, Shi SB.

Zhonghua Yi Xue Za Zhi. 2008 Mar 11;88(10):669-73. Chinese.

PMID:
18642766

Supplemental Content

Support Center